Jagsonpal Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
JAGSNPHARM
Pharmaceuticals
Screen Jagsonpal Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹186.65
▼
-3.50 (-1.84%)
Share Price BSE
₹187.05
▼
-3.05 (-1.60%)
Market Cap
₹1,296.42 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.09
EPS (TTM)
₹8.26
Dividend Yield
1.29%
Debt to Equity
0.04
52W High
₹292.75
52W Low
₹186.65
Operating Margin
19.00%
Profit Margin
19.56%
Revenue (TTM)
₹317.00
EBITDA
₹89.00
Net Income
₹62.00
Total Assets
₹278.00
Total Equity
₹240.00
Jagsonpal Pharmaceuticals Share Price History - Stock Screener Chart
Screen JAGSNPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Jagsonpal Pharmaceuticals Company Profile - Fundamental Screener
Screen Jagsonpal Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JAGSNPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE048B01035
Jagsonpal Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen JAGSNPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 278 | 217 | 195 | 164 | 164 | 147 | 136 | 130 | 143 | 159 |
| Current Assets | 161 | 199 | 165 | 109 | 121 | 95 | 98 | 95 | 110 | 101 |
| Fixed Assets | 95 | 9 | 24 | 23 | 26 | 22 | 22 | 21 | 22 | 52 |
| Liabilities | ||||||||||
| Total Liabilities | 278 | 217 | 195 | 164 | 164 | 147 | 136 | 130 | 143 | 159 |
| Current Liabilities | 12 | 11 | 9 | 5 | 2 | 3 | 3 | 3 | 3 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 240 | 187 | 159 | 133 | 122 | 111 | 105 | 98 | 110 | 98 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 226 | 174 | 146 | 120 | 109 | 98 | 91 | 85 | 97 | 85 |
Screen JAGSNPHARM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 317 | 277 | 218 | 242 | 221 | 192 | 161 | 168 | 127 | 144 | 144 | 138 |
| Expenses | 228 | 218 | 186 | 203 | 193 | 169 | 150 | 158 | 138 | 138 | 132 | 129 |
| EBITDA | 89 | 59 | 32 | 40 | 29 | 24 | 11 | 11 | -11 | 6 | 13 | 9 |
| Operating Profit % | 19.00% | 19.00% | 11.00% | 14.00% | 12.00% | 10.00% | 5.00% | 6.00% | -9.00% | 4.00% | 8.00% | 6.00% |
| Depreciation | 9 | 8 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 2 | 3 | 3 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 5 | 5 |
| Profit Before Tax | 79 | 70 | 30 | 35 | 27 | 22 | 9 | 9 | -12 | 14 | 4 | 2 |
| Tax | 16 | 15 | 7 | 8 | 8 | 5 | 2 | 2 | 0 | 3 | 1 | 1 |
| Net Profit | 62 | 55 | 23 | 27 | 19 | 17 | 8 | 7 | -12 | 12 | 3 | 1 |
| EPS | 9.20 | 8.26 | 8.49 | 10.20 | 7.20 | 6.51 | 3.00 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 |
Jagsonpal Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen JAGSNPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 55 | 35 | 47 | 7 | 28 | 11 | 31 | -2 | -3 | 9 |
| Investing Activities | -45 | -25 | -58 | -26 | -2 | -11 | -1 | -3 | 41 | -2 |
| Financing Activities | -12 | -9 | -1 | -18 | -7 | -1 | -6 | -1 | -34 | -6 |
| Net Cash Flow | -2 | 2 | -12 | -36 | 19 | -1 | 24 | -6 | 5 | 1 |
Screen JAGSNPHARM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 67.78% | 67.65% | 67.54% | 68.09% | 68.04% | 67.97% | 67.81% | 68.71% |
| FII Holding | 2.10% | 2.18% | 2.12% | 0.73% | 1.10% | 2.30% | 2.10% | 0.00% |
| DII Holding | 0.00% | 0.05% | 0.09% | 0.85% | 0.85% | 0.11% | 0.00% | 0.83% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 20.94% | 24.26% | 21.13% | 20.69% | 20.79% | 20.38% | 20.64% | 22.23% |
| Other Holding | 9.17% | 5.86% | 9.12% | 9.64% | 9.22% | 9.24% | 9.45% | 8.23% |
| Shareholder Count | 21,085 | 22,899 | 24,653 | 16,282 | 15,748 | 15,633 | 18,471 | 14,084 |
Jagsonpal Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen JAGSNPHARM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹2.50 | 1.30% |
| 2024-March | ₹5.00 | 2.30% |
| 2023-March | ₹5.00 | 4.52% |
| 2022-March | ₹4.00 | 3.45% |
| 2021-March | ₹1.00 | 0.80% |
| 2020-March | ₹0.50 | 1.57% |
| 2019-March | ₹0.25 | 3.56% |
| 2018-March | ₹0.10 | 0.95% |
| 2017-March | ₹0.10 | 0.93% |
Jagsonpal Pharmaceuticals Index Membership - Market Screener Classification
Screen JAGSNPHARM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Jagsonpal Pharmaceuticals Market Events Screener - Corporate Actions
Screen JAGSNPHARM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 13.48% | ||
| Dividend | ₹ 1.00 /share | 0.16% | ||
| Annual General Meeting | NA | -8.13% | ||
| Dividend | ₹ 2.50 /share | -0.89% | ||
| Dividend | ₹ 5.00 /share | 15.69% | ||
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 3.12% |
| 2025-07-26 | 2025-07-26 | Quarterly Result Announcement | NA | 0.30% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 7.55% |
| 2025-01-22 | 2025-01-22 | Quarterly Result Announcement | NA | 3.14% |
| 2025-01-08 | 2024-10-23 | Split | 2:5 | 0.00% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | 1.14% |
| 2023-08-21 | 2023-08-21 | Dividend | ₹ 5.00 /share | 29.50% |
| 2022-06-17 | 2022-06-17 | Extraordinary General Meeting | NA | -5.78% |
| 2021-10-29 | 2021-11-01 | Dividend | ₹ 4.00 /share | 7.54% |
Jagsonpal Pharmaceuticals Competitors Screener - Peer Comparison
Screen JAGSNPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 414,605 | 39.37 | 54,729 | 9.71% | 10,980 | 42.10 |
| Divis Laboratories | 169,701 | 67.76 | 9,712 | 18.67% | 2,191 | 48.20 |
| Torrent Pharmaceuticals | 131,496 | 60.85 | 11,539 | 6.99% | 1,911 | 67.66 |
| Cipla | 122,103 | 22.30 | 28,410 | 7.12% | 5,291 | 51.10 |
| Dr Reddys Laboratories | 104,838 | 18.24 | 33,741 | 16.73% | 5,725 | 45.31 |
| Lupin | 96,170 | 22.10 | 22,910 | 13.74% | 3,306 | 56.06 |
| Zydus Life Science | 92,262 | 18.30 | 23,511 | 18.55% | 4,615 | 45.37 |
| Mankind Pharma | 90,929 | 50.34 | 12,744 | 20.90% | 2,007 | 50.55 |
| Aurobindo Pharma | 70,591 | 20.25 | 32,346 | 9.43% | 3,484 | 56.45 |
| Alkem Laboratories | 66,867 | 27.11 | 13,458 | 3.70% | 2,216 | 50.91 |
Jagsonpal Pharmaceuticals Company Announcements - News Screener
Screen JAGSNPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-04 | Announcement Under Regulation 30 Of SEBI (LODR) 2015 | View |
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-03 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-03 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-27 | Board Meeting Intimation for Intimation For Board Meeting. | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-07 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-10-07 | Intimation Under Regulation 30 (5) Of The SEBI (LODR) Regulations 2015 | View |
| 2025-10-07 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-26 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |